Gubra A/S (GUBRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gubra A/S (GUBRA) has a cash flow conversion efficiency ratio of -0.519x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-594.98 Million ≈ $-93.09 Million USD) by net assets (Dkr1.15 Billion ≈ $179.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gubra A/S (GUBRA) net asset quality to measure how much of total assets are equity-financed.
Gubra A/S - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Gubra A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GUBRA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Gubra A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gubra A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
N/A |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
N/A |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
0.013x |
|
Hanma Technology Group Co Ltd
SHG:600375
|
-0.016x |
|
Fiyta Holdings Ltd
SHE:000026
|
0.049x |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
0.057x |
|
Aerosun Corp
SHG:600501
|
0.128x |
|
Dalian Insulator Group Co Ltd
SHE:002606
|
0.030x |
Annual Cash Flow Conversion Efficiency for Gubra A/S (2020–2025)
The table below shows the annual cash flow conversion efficiency of Gubra A/S from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Gubra A/S market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr1.15 Billion ≈ $179.29 Million |
Dkr1.71 Billion ≈ $267.91 Million |
1.494x | +13314.80% |
| 2024-12-31 | Dkr450.57 Million ≈ $70.50 Million |
Dkr5.02 Million ≈ $785.26K |
0.011x | +110.81% |
| 2023-12-31 | Dkr479.66 Million ≈ $75.05 Million |
Dkr-49.42 Million ≈ $-7.73 Million |
-0.103x | -145.80% |
| 2022-12-31 | Dkr108.21 Million ≈ $16.93 Million |
Dkr24.34 Million ≈ $3.81 Million |
0.225x | -61.51% |
| 2021-12-31 | Dkr151.46 Million ≈ $23.70 Million |
Dkr88.51 Million ≈ $13.85 Million |
0.584x | +41.74% |
| 2020-12-31 | Dkr80.01 Million ≈ $12.52 Million |
Dkr32.99 Million ≈ $5.16 Million |
0.412x | -- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more